Imagine this: a patient finishes a prescreening form on a Tuesday morning. Twenty-five minutes later, the site calls. It's textbook speed-to-lead! This is the site's MO: most referrals it receives receive a swift ring. The patient doesn't pick up, though. Neither
💡Our data suggests that a small gap in how some sites screen for PTSD history could be costing MDD trials as much as 15% of otherwise viable screening appointments. Read on to learn why. It’s an exciting time in MDD research. At Power, we’ve worked on over 50%
Newsletter
“Site archetype” tells us how many referrals to initially send to a site. How a site actually acts on its first two months of referrals tells us how to update.
Newsletter
Not every enrollment slowdown is a site problem. Sometimes it's a portfolio problem. Here's how to tell the difference and what to do about it.
Podcast
How Sonia Prashar Built a Mission Around Mental Health
Newsletter
Your local call center knows exactly how every agent performed today. Your clinical trial sites? They're still filling out spreadsheets.
Newsletter
"The last paragraph in a paper is often what you really want to be doing,"
Newsletter
In 1996, a young psychiatrist named Joseph Palumbo joined Cephalon to work on myotrophin, a promising ALS candidate. It didn't succeed. What he learned shaped the first ALS approval in over 20 years.
Newsletter
How "positive deviance" can help you find what's working and scale it
Newsletter
The operational insights behind our biggest year in patient recruitment
Newsletter
How a time-constrained 6-month proof-of-concept study and disciplined trial methodology transformed a shelved compound into a $14 billion breakthrough
Newsletter
Why patients who seem "engaged" disappear... and what site behaviors may be driving them away